Abstract “Liquid biopsy” focusing on the analysis of circulating tumor cells (CTC) and
circulating cell-free tumor DNA (ctDNA) in the blood of patients with cancer has received …

While various clinical applications especially in oncology are now in progress such as
diagnosis, prognosis, therapy monitoring, or patient follow-up, the determination of structural …

Colorectal cancer (CRC) is one of the most common malignancies in Western countries.
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …

The genomic landscape of breast cancer is complex, and inter-and intra-tumour
heterogeneity are important challenges in treating the disease. In this study, we sequence …

Malignant tumors shed DNA into the circulation. The transient half-life of circulating tumor
DNA (ctDNA) may afford the opportunity to diagnose, monitor recurrence, and evaluate …

Purpose ESR1 mutations are selected by prior aromatase inhibitor (AI) therapy in advanced
breast cancer. We assessed the impact of ESR1 mutations on sensitivity to standard …

Minimally invasive detection of cell death could prove an invaluable resource in many
physiologic and pathologic situations. Cell-free circulating DNA (cfDNA) released from dying …

Importance Plasma genotyping of cell-free DNA has the potential to allow for rapid
noninvasive genotyping while avoiding the inherent shortcomings of tissue genotyping and …

High-throughput sequencing of circulating tumor DNA (ctDNA) promises to facilitate
personalized cancer therapy. However, low quantities of cell-free DNA (cfDNA) in the blood …

Metastasis is a biologically complex process consisting of numerous stochastic events which
may tremendously differ across various cancer types. Circulating tumor cells (CTCs) are …